Evidence map›Paper›PMID 29893888›Full record

ArticleThe Journal of infectious diseases2018

Intradermal Vaccination With Adjuvanted Ebola Virus Soluble Glycoprotein Subunit Vaccine by Microneedle Patches Protects Mice Against Lethal Ebola Virus Challenge.

Ying Liu, Ling Ye, Fang Lin, Yasmine Gomaa, David Flyer, Ricardo Carrion, Jean L Patterson, Mark R Prausnitz, Gale Smith, Gregory Glenn and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Progress in microneedle array patch (MAP) for vaccine delivery.Human vaccines & immunotherapeutics · 2021
    Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Microneedle Coating Methods: A Review with a Perspective.The Journal of pharmacology and experimental therapeutics · 2019
    Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Ying LiuKey Laboratory of Special Animal Epidemic Disease, Ministry of Agriculture, Institute of Special Economic Animals and Plants, Chinese Academy of Agricultural Sciences (CAAS), Changchun, Jilin, China.
Ling YeEmory University School of Medicine, Atlanta, Georgia.
Fang LinEmory University School of Medicine, Atlanta, Georgia.
Yasmine GomaaSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta.
David FlyerNovavax Inc., Gaithersburg, Maryland.
Ricardo CarrionTexas Biomedical Research Institute, San Antonio.
Jean L PattersonTexas Biomedical Research Institute, San Antonio.
Mark R PrausnitzSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta.
Gale SmithNovavax Inc., Gaithersburg, Maryland.
Gregory GlennNovavax Inc., Gaithersburg, Maryland.
Hua WuKey Laboratory of Special Animal Epidemic Disease, Ministry of Agriculture, Institute of Special Economic Animals and Plants, Chinese Academy of Agricultural Sciences (CAAS), Changchun, Jilin, China.
Richard W CompansEmory University School of Medicine, Atlanta, Georgia.
Chinglai YangEmory University School of Medicine, Atlanta, Georgia.
Emory University · USNovavax (United States) · USGeorgia Institute of Technology · USTexas Biomedical Research Institute · USChinese Academy of Agricultural Sciences · CNInstitute of Special Animal and Plant Sciences · CN

Funding

A dual vaccine strategy against filovirus infectionR01AI093406 · NIAID · EMORY UNIVERSITY · PI COMPANS, RICHARD W · 2011 to 2015
$5.1M
NIAID NIH HHS R01 AI093406
6 · The paper itself

Abstract

In this study, we investigated immune responses induced by purified Ebola virus (EBOV) soluble glycoprotein (sGP) subunit vaccines via intradermal immunization with microneedle (MN) patches in comparison with intramuscular (IM) injection in mice. Our results showed that MN delivery of EBOV sGP was superior to IM injection in eliciting higher levels and longer lasting antibody responses against EBOV sGP and GP antigens. Moreover, sGP-specific immune responses induced by MN or IM immunizations were effectively augmented by formulating sGP with a saponin-based adjuvant, and they were shown to confer complete protection of mice against lethal mouse-adapted EBOV (MA-EBOV) challenge. In comparison, mice that received sGP without adjuvant by MN or IM immunizations succumbed to lethal MA-EBOV challenge. These results show that immunization with EBOV sGP subunit vaccines with adjuvant by MN patches, which have been shown to provide improved safety and thermal stability, is a promising approach to protect against EBOV infection.

Indexed as

VaccinationAdjuvants, ImmunologicAnimalsAntibodies, ViralAntibody FormationEbola VaccinesFemaleHEK293 CellsHeLa CellsHemorrhagic Fever, EbolaHumansInjections, IntramuscularMiceMice, Inbred BALB CVaccines, SubunitAdjuvants, ImmunologicAntibodies, ViralEbola VaccinesVaccines, Subunit

Identifiers

PMID29893888
PMCPMC6249567
OpenAlexW2806840995

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.